Helmout Modjtahedi

Summary

Affiliation: Kingston University
Country: UK

Publications

  1. doi request reprint Therapeutic application of monoclonal antibodies in cancer: advances and challenges
    Helmout Modjtahedi
    School of Life Sciences, Kingston University London, Penrhyn Road, Kingston KT12EE, UK
    Br Med Bull 104:41-59. 2012
  2. pmc Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells
    Nikolaos Ioannou
    School of Life Sciences, Kingston University London, Kingston upon Thames, Surrey KT1 2EE, UK
    BMC Cancer 13:41. 2013
  3. ncbi request reprint Prognostic significance and targeting of HER family in colorectal cancer
    Said Abdullah Khelwatty
    School of Life Sciences, Kingston University London, Kingston upon Thames, Surrey KT1 2EE, United Kingdom
    Front Biosci (Landmark Ed) 18:394-421. 2013
  4. pmc Co-expression of HER family members in patients with Dukes' C and D colon cancer and their impacts on patient prognosis and survival
    Said Abdullah Khelwatty
    School of Life Sciences, Kingston University London, Kingston, United Kingdom
    PLoS ONE 9:e91139. 2014
  5. doi request reprint Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members
    Said Abdullah Khelwatty
    School of Life Sciences, Kingston University London, Kingston, Surrey, UK
    Int J Oncol 39:483-91. 2011
  6. ncbi request reprint Expression pattern and targeting of HER family members and IGF-IR in pancreatic cancer
    Nikolaos Ioannou
    School of Life Sciences, Kingston University London, Kingston, UK
    Front Biosci (Landmark Ed) 17:2698-724. 2012
  7. ncbi request reprint Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities
    Helmout Modjtahedi
    School of Life Sciences, Faculty of Science, Kingston University London, Kingston upon Thames, Surrey KT1 2EE, UK
    Anticancer Drugs 20:851-5. 2009

Collaborators

  • Nikolaos Ioannou
  • Said Abdullah Khelwatty
  • Sharadah Essapen
  • Alan Michael Seddon
  • Margaret Green
  • Izhar Bagwan
  • Alan M Seddon

Detail Information

Publications7

  1. doi request reprint Therapeutic application of monoclonal antibodies in cancer: advances and challenges
    Helmout Modjtahedi
    School of Life Sciences, Kingston University London, Penrhyn Road, Kingston KT12EE, UK
    Br Med Bull 104:41-59. 2012
    ..Monoclonal antibody (mAb)-based products are highly specific for a particular antigen. This characteristic feature of the molecules makes them an ideal tool for many applications including cancer diagnosis and therapy...
  2. pmc Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells
    Nikolaos Ioannou
    School of Life Sciences, Kingston University London, Kingston upon Thames, Surrey KT1 2EE, UK
    BMC Cancer 13:41. 2013
    ..In this study, we investigated the effect of simultaneous targeting of IGF-IR and HER (erbB) family, with NVP-AEW541 and afatinib, on proliferation of pancreatic cancer cells...
  3. ncbi request reprint Prognostic significance and targeting of HER family in colorectal cancer
    Said Abdullah Khelwatty
    School of Life Sciences, Kingston University London, Kingston upon Thames, Surrey KT1 2EE, United Kingdom
    Front Biosci (Landmark Ed) 18:394-421. 2013
    ..g. dual and pan HER TKIs, monospecific or bispecific antibodies) in combination with other therapeutic interventions...
  4. pmc Co-expression of HER family members in patients with Dukes' C and D colon cancer and their impacts on patient prognosis and survival
    Said Abdullah Khelwatty
    School of Life Sciences, Kingston University London, Kingston, United Kingdom
    PLoS ONE 9:e91139. 2014
    ....
  5. doi request reprint Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members
    Said Abdullah Khelwatty
    School of Life Sciences, Kingston University London, Kingston, Surrey, UK
    Int J Oncol 39:483-91. 2011
    ..This approach could lead to the identification of a specific subpopulation of cancer patients more likely to benefit from erbB-directed therapy...
  6. ncbi request reprint Expression pattern and targeting of HER family members and IGF-IR in pancreatic cancer
    Nikolaos Ioannou
    School of Life Sciences, Kingston University London, Kingston, UK
    Front Biosci (Landmark Ed) 17:2698-724. 2012
    ..Such strategies could ultimately help to overcome the development of drug resistance and improve the overall survival rates for patients with pancreatic cancer...
  7. ncbi request reprint Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities
    Helmout Modjtahedi
    School of Life Sciences, Faculty of Science, Kingston University London, Kingston upon Thames, Surrey KT1 2EE, UK
    Anticancer Drugs 20:851-5. 2009
    ....